DFFN - Diffusion Pharmaceuticals' TSC: Thoughts On The Potential For Its Glioblastoma Indication
Background
Cancers of the brain (gliomas) are rare, yet fast-growing and deadly. Per a thorough 2017 study, the incidence rate is 22.64 Americans per 100,000 population.
Although there has been some success with NovoCure's (NVCR) Optune system (more on this later), multiple recent drug treatment trials in this area have failed; e.g.: VBL Therapeutics' March 2018 Phase 3 failure in recurrent glioblastoma, and more recently, well-funded Tocagen's (TOCA) Phase 3 failure in high-grade glioma (which encompasses glioblastoma, astrocytoma, and oligodendroglioma). Tocagen was worth at one point approximately $17.40 share, but now the stock